Fusion of Mature HIV-1 Particles Leads to Complete Release of a Gag-GFP-Based Content Marker and Raises the Intraviral pH

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Padilla Parra, Sergi ^a,c   Marin, Mariana ^a   Gahlaut, Nivriti ^a   Suter, Rolf ^a,d   Kondo, Naoyuki ^a,e   Melikyan, Gregory B ^a,b  

^a EMORY UNIVERSITY   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d GEORGIA STATE UNIVERSITY   (United States)

^e KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GAG PROTEIN; GREEN FLUORESCENT PROTEIN; SAPONIN; VIRUS RNA;

ARTICLE; CELL FUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISSOCIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MATURATION; NONHUMAN; PH; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; VIRUS CAPSID; VIRUS ENTRY; VIRUS PARTICLE;

EID: 84881229466     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071002     Document Type: Article

References (63)

1. Bieniasz PD, Cullen BR, (1998) Chemokine receptors and human immunodeficiency virus infection. Front Biosci 3: d44-58.
2. Berger EA, Murphy PM, Farber JM, (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17: 657-700.
3. Aiken C, (2006) Viral and cellular factors that regulate HIV-1 uncoating. Curr Opin HIV AIDS 1: 194-199.
4. Fassati A (2012) Multiple roles of the capsid protein in the early steps of HIV-1 infection. Virus Res.
5. Stein BS, Gowda SD, Lifson JD, Penhallow RC, Bensch KG, et al. (1987) pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell 49: 659-668.
6. McClure MO, Marsh M, Weiss RA, (1988) Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. Embo J 7: 513-518.
7. Brandt SM, Mariani R, Holland AU, Hope TJ, Landau NR, (2002) Association of chemokine-mediated block to HIV entry with coreceptor internalization. J Biol Chem 277: 17291-17299.
8. Bedinger P, Moriarty A, von Borstel RC 2nd, Donovan NJ, Steimer KS, et al. (1988) Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4. Nature 334: 162-165.
9. Maddon PJ, McDougal JS, Clapham PR, Dalgleish AG, Jamal S, et al. (1988) HIV infection does not require endocytosis of its receptor, CD4. Cell 54: 865-874.
10. Pelchen-Matthews A, Clapham P, Marsh M, (1995) Role of CD4 endocytosis in human immunodeficiency virus infection. J Virol 69: 8164-8168.
11. de la Vega M, Marin M, Kondo N, Miyauchi K, Kim Y, et al. (2011) Inhibition of HIV-1 endocytosis allows lipid mixing at the plasma membrane, but not complete fusion. Retrovirology 8: 99.
12. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB, (2009) HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137: 433-444.
13. Daecke J, Fackler OT, Dittmar MT, Krausslich HG, (2005) Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry. J Virol 79: 1581-1594.
14. Carter GC, Bernstone L, Baskaran D, James W, (2011) HIV-1 infects macrophages by exploiting an endocytic route dependent on dynamin, Rac1 and Pak1. Virology 409: 234-250.
15. Kadiu I, Gendelman HE, (2011) Human immunodeficiency virus type 1 endocytic trafficking through macrophage bridging conduits facilitates spread of infection. J Neuroimmune Pharmacol 6: 658-675.
16. Schaeffer E, Soros VB, Greene WC, (2004) Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes. J Virol 78: 1375-1383.
17. von Kleist L, Stahlschmidt W, Bulut H, Gromova K, Puchkov D, et al. (2011) Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell 146: 471-484.
18. Clotet-Codina I, Bosch B, Senserrich J, Fernandez-Figueras MT, Pena R, et al. (2009) HIV endocytosis after dendritic cell to T cell viral transfer leads to productive virus infection. Antiviral Res 83: 94-98.
19. Hubner W, McNerney GP, Chen P, Dale BM, Gordon RE, et al. (2009) Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science 323: 1743-1747.
20. Sloan RD, Kuhl BD, Mesplede T, Munch J, Donahue DA, et al. (2013) Productive entry of HIV-1 during cell-to-cell transmission via dynamin-dependent endocytosis. J Virol.
21. Permanyer M, Ballana E, Badia R, Pauls E, Clotet B, et al. (2012) Trans-infection but not infection from within endosomal compartments after cell-to-cell HIV-1 transfer to CD4+ T cells. J Biol Chem.
22. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ, (2004) HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 199: 283-293.
23. Wild C, Greenwell T, Shugars D, Rimsky-Clarke L, Matthews T, (1995) The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure [letter]. AIDS Res Hum Retroviruses 11: 323-325.
24. Demirkhanyan LH, Marin M, Padilla-Parra S, Zhan C, Miyauchi K, et al. (2012) Multifaceted mechanisms of HIV-1 entry inhibition by human alpha-defensin. J Biol Chem.
25. Hubner W, Chen P, Del Portillo A, Liu Y, Gordon RE, et al. (2007) Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication-competent, fluorescently tagged HIV-1. J Virol 81: 12596-12607.
26. Dale BM, McNerney GP, Thompson DL, Hubner W, de Los Reyes K, et al. (2011) Cell-to-cell transfer of HIV-1 via virological synapses leads to endosomal virion maturation that activates viral membrane fusion. Cell Host Microbe 10: 551-562.
27. Yu Z, Dobro MJ, Woodward CL, Levandovsky A, Danielson CM, et al. (2013) Unclosed HIV-1 capsids suggest a curled sheet model of assembly. J Mol Biol 425: 112-123.
28. Campbell EM, Perez O, Anderson JL, Hope TJ, (2008) Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J Cell Biol 180: 549-561.
29. Ganser-Pornillos BK, Chandrasekaran V, Pornillos O, Sodroski JG, Sundquist WI, et al. (2011) Hexagonal assembly of a restricting TRIM5alpha protein. Proc Natl Acad Sci U S A 108: 534-539.
30. Padilla-Parra S, Marin M, Kondo N, Melikyan GB, (2012) Synchronized Retrovirus Fusion in Cells Expressing Alternative Receptor Isoforms Releases the Viral Core into Distinct Sub-cellular Compartments. PLoS Pathog 8: e1002694.
31. Kozak SL, Platt EJ, Madani N, Ferro FE Jr, Peden K, et al. (1997) CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol 71: 873-882.
32. Shi J, Zhou J, Shah VB, Aiken C, Whitby K, (2011) Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol 85: 542-549.
33. Deng Y, Zheng Q, Ketas TJ, Moore JP, Lu M, (2007) Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry 46: 4360-4369.
34. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
35. Chesebro B, Wehrly K, Nishio J, Perryman S, (1992) Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol 66: 6547-6554.
36. Malim MH, Hauber J, Fenrick R, Cullen BR, (1988) Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature 335: 181-183.
37. Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC, et al. (2003) Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol 77: 5678-5684.
38. Melikyan GB, Barnard RJ, Abrahamyan LG, Mothes W, Young JA, (2005) Imaging individual retroviral fusion events: from hemifusion to pore formation and growth. Proc Natl Acad Sci U S A 102: 8728-8733.
39. Miyauchi K, Marin M, Melikyan GB, (2011) Visualization of retrovirus uptake and delivery into acidic endosomes. Biochem J 434: 559-569.
40. Sherer NM, Lehmann MJ, Jimenez-Soto LF, Ingmundson A, Horner SM, et al. (2003) Visualization of retroviral replication in living cells reveals budding into multivesicular bodies. Traffic 4: 785-801.
41. Markosyan RM, Cohen FS, Melikyan GB, (2005) Time-resolved imaging of HIV-1 Env-mediated lipid and content mixing between a single virion and cell membrane. Mol Biol Cell 16: 5502-5513.
42. Hammonds J, Chen X, Zhang X, Lee F, Spearman P, (2007) Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines. Vaccine 25: 8036-8048.
43. Llopis J, McCaffery JM, Miyawaki A, Farquhar MG, Tsien RY, (1998) Measurement of cytosolic, mitochondrial, and Golgi pH in single living cells with green fluorescent proteins. Proc Natl Acad Sci U S A 95: 6803-6808.
44. Jha NK, Latinovic O, Martin E, Novitskiy G, Marin M, et al. (2011) Imaging single retrovirus entry through alternative receptor isoforms and intermediates of virus-endosome fusion. PLoS Pathog 7: e1001260.
45. Francis G, Kerem Z, Makkar HP, Becker K, (2002) The biological action of saponins in animal systems: a review. Br J Nutr 88: 587-605.
46. Fassati A, Goff SP, (2001) Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol 75: 3626-3635.
47. Morellet N, Roques BP, Bouaziz S, (2009) Structure-function relationship of Vpr: biological implications. Curr HIV Res 7: 184-210.
48. Shaner NC, Steinbach PA, Tsien RY, (2005) A guide to choosing fluorescent proteins. Nat Methods 2: 905-909.
49. Forshey BM, Aiken C, (2003) Disassembly of human immunodeficiency virus type 1 cores in vitro reveals association of Nef with the subviral ribonucleoprotein complex. J Virol 77: 4409-4414.
50. Mothes W, Boerger AL, Narayan S, Cunningham JM, Young JA, (2000) Retroviral entry mediated by receptor priming and low pH triggering of an envelope glycoprotein. Cell 103: 679-689.
51. Melikyan GB, Barnard RJ, Markosyan RM, Young JA, Cohen FS, (2004) Low pH Is Required for Avian Sarcoma and Leukosis Virus Env-Induced Hemifusion and Fusion Pore Formation but Not for Pore Growth. J Virol 78: 3753-3762.
52. Padilla-Parra S, Matos PM, Kondo N, Marin M, Santos NC, et al. (2012) Quantitative imaging of endosome acidification and single retrovirus fusion with distinct pools of early endosomes. Proc Natl Acad Sci U S A 109: 17627-17632.
53. Bates P, Young JA, Varmus HE, (1993) A receptor for subgroup A Rous sarcoma virus is related to the low density lipoprotein receptor. Cell 74: 1043-1051.
54. Narayan S, Barnard RJ, Young JA, (2003) Two retroviral entry pathways distinguished by lipid raft association of the viral receptor and differences in viral infectivity. J Virol 77: 1977-1983.
55. Matsuyama S, Delos SE, White JM, (2004) Sequential roles of receptor binding and low pH in forming prehairpin and hairpin conformations of a retroviral envelope glycoprotein. J Virol 78: 8201-8209.
56. Smith JG, Mothes W, Blacklow SC, Cunningham JM, (2004) The mature avian leukosis virus subgroup A envelope glycoprotein is metastable, and refolding induced by the synergistic effects of receptor binding and low pH is coupled to infection. J Virol 78: 1403-1410.
57. Moolenaar WH, Tsien RY, van der Saag PT, de Laat SW, (1983) Na+/H+ exchange and cytoplasmic pH in the action of growth factors in human fibroblasts. Nature 304: 645-648.
58. Wyma DJ, Jiang J, Shi J, Zhou J, Lineberger JE, et al. (2004) Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J Virol 78: 3429-3435.
59. Kaczmarczyk SJ, Sitaraman K, Young HA, Hughes SH, Chatterjee DK, (2011) Protein delivery using engineered virus-like particles. Proc Natl Acad Sci U S A 108: 16998-17003.
60. Murakami T, Ablan S, Freed EO, Tanaka Y, (2004) Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity. J Virol 78: 1026-1031.
61. Muller B, Anders M, Akiyama H, Welsch S, Glass B, et al. (2009) HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J Biol Chem 284: 29692-29703.
62. Lee SK, Potempa M, Swanstrom R, (2012) The choreography of HIV-1 proteolytic processing and virion assembly. J Biol Chem 287: 40867-40874.
63. Checkley MA, Luttge BG, Soheilian F, Nagashima K, Freed EO, (2010) The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation. Virology 400: 137-144.